Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID

References

• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
   PubMed Web of Science ®Google Scholar
• Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999;159:1873-80
   PubMed Web of Science ®Google Scholar
• Simpson SH, Corabian P, Jacobs P, et al. The cost of major comorbidity in people with diabetes mellitus. CMAJ 2003;168:1661-7
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Menzin J, Langley-Hawthorne C, Friedman M, et al. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 2001;24:51-5
   PubMed Web of Science ®Google Scholar
• Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285:182-9
   PubMed Web of Science ®Google Scholar
• Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm 2005;11:559-64
   PubMedGoogle Scholar
• Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-44
   PubMed Web of Science ®Google Scholar
• Blickle JF, Hancu N, Piletic M, et al. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. Diabetes Obes Metab 2009;11:379-86
   PubMed Web of Science ®Google Scholar
• Davies M, Lavalle-Gonzalez F, Storms F, et al. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab 2008;10:387-99
   PubMed Web of Science ®Google Scholar
• Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007;9:31-8
   PubMed Web of Science ®Google Scholar
• Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010;33:1176-8
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006;29:554-9
   PubMed Web of Science ®Google Scholar
• Meneghini LF, Taylor L, Schwartz S. Improved glycemic control with insulin glargine vs pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes. Endocr Pract 2010;16:588-99
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
   Web of Science ®Google Scholar
• Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009;25:777-86
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
   PubMed Web of Science ®Google Scholar
• Lantus [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC, 2009
   Google Scholar
• BYETTA [prescribing information]. San Diego, CA: Amylin Pharmaceuticals, Inc., 2009
   Google Scholar
• Brunton SA, Davis SN, Renda SM. Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone 2006;8(Suppl 2):S19-S26
   PubMedGoogle Scholar
• Carter J, Roberts A. Usability of a pre-filled insulin injection device in a 3-month observational survey of everyday clinical practice in Australia. Curr Med Res Opin 2008;24:2741-9
   PubMed Web of Science ®Google Scholar
• Fischer JS, Edelman SV, Schwartz SL. United States patient preference and usability for the new disposable insulin device Solostar versus other disposable pens. J Diabetes Sci Technol 2008;2:1157-60
   PubMedGoogle Scholar
• Misurski D, Lage MJ, Fabunmi R, et al. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. Appl Health Econ Health Policy 2009;7:245-54
   PubMedGoogle Scholar
• Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43
   PubMed Web of Science ®Google Scholar
• Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29:2333-48
   PubMed Web of Science ®Google Scholar
• Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared to insulin glargine, in metformin treated type 2 diabetes patients: a randomized, controlled trial. Diabetes Care 2009;32:762-68
   PubMed Web of Science ®Google Scholar
• Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-112
   PubMed Web of Science ®Google Scholar